Axillary artery loop interposition graft (AALG) as unusual access for hemodialysis

Abdelmieniem Fareed, Nehad Zaid, Yahia M. Alkhateep*

INTRODUCTION

The number of patients with end-stage renal disease (ESRD) requiring hemodialysis is constantly rising worldwide.¹ Vascular hemodialysis access is considered the lifeline for patients with end-stage renal disease, and arteriovenous fistula (AVF) has been the golden standard access for hemodialysis.² In Europe, over 25% of all hospital admissions for ESRD are for the construction or maintenance of a patent vascular hemodialysis access.³

While the life expectancy of ESRD patients continues to lengthen and with the limited durability of vascular accesses, repeat fistula construction at different levels of the upper limb is often necessary and leads ultimately to exhaustion of autogenous vascular access sites.⁴ Use of a synthetic prosthesis is currently the recommended treatment alternative for patients who have exhausted all native fistulas access options, however, such grafts have lower patency rates and shorter lifetimes than autogenous arteriovenous fistulas.⁵

The use of an artery as permanent vascular access for hemodialysis is not a new procedure; Brittinger et al, used the subcutaneously fixed superficial femoral artery for needle puncture.⁶ Butt and Kountz reported satisfactory results with an arterial femoropopliteal graft that used a bovine carotid artery as vascular access in seven patients.² Our experience with alternative vascular access procedures namely the arterio-arterial loop graft in...
the first part of axillary artery was presented in this study.

METHODS

From June 2013 to Aug 2017, arterio-arterial interposition loop graft procedures (AALG) for vascular access were performed in 15 patients with end-stage renal disease. All patients were initially assessed in our vascular unit clinic in Menoufia University Hospital. It was essential to use duplex scanning of arteries to define adequacy of arteries. Written informed consent was taken from all patients before the procedure. The committee of human research approved the study.

Inclusion criteria were patients with unsuitable large deep veins (subclavian, internal jugular, and femoral veins), either all six veins, or five out of six veins in younger patients with good prognosis (the last suitable vein should be reserved as an access for a central venous catheter in emergency). A vein is considered unsuitable if an occlusion or high-grade long stenosis (<70% in diameter, >4 cm long) of the vein or the venous outflow obstruction is detected and cannot be treated promisingly by any interventions. Patients with cardiac insufficiency that is intolerable to the additional cardiac load of a high-flow AV fistula were also enrolled.

Exclusion criteria were patients with chronic ischemia of the limb, infection or huge ugly scar at loop site.

All procedures were performed under general anesthesia. Two grams of 3rd generation antibiotic was administered with induction of anesthesia. The operative procedures included exposure of the first part of axillary artery, after separation of the artery, a PTFE graft with a 6- or 8-mm diameter (adapted to the diameter of the artery) was interposition after configuration of a subcutaneously tunneled loop on the chest wall (Figure 1).

A 6/0 polypropylene suture was used in the creation of an end-artery to end-graft anastomoses between the ends of prosthesis and the first part of axillary artery (Figure 2). The length of the implanted graft was between 30 and 40 cm. The mean operation time was 102 minutes. Low molecular weight heparin therapeutic dose was administered once a day for five days then was replaced by oral anticoagulation warfarin for lifelong. The first needle puncture of the graft was carried out not before two weeks after the procedure.

Statistical analysis

Statistical analysis performed using SPSS v. 24.0. (IBM Corp., USA). Discrete variables presented as numbers (counts) and percent. Continuous variables presented as mean and standard deviation (SD). Student T-test was used for intergroup comparisons to test the significance of difference between two different variables. P<0.05 was considered statistically significant. The Kaplan-Meier method was used to compute graft patency.

RESULTS

Fifteen patients had arterio-arterial axillary loop grafts in the period from 2013 till 2017 which represent about 0.3% of all vascular accesses done during this period in
our department. The ePTFE Grafts were used for hemodialysis two weeks following the surgery. The mean patient age was 58±13 years; 60% were women. Comorbid conditions included diabetes mellitus (66.7%), coronary artery disease (60%), and hyperlipidemia (53.3%) (Table 1).

Table 1: Patients’ demographic and clinical data.

| Variable                        | N   | Age (years, mean±SD)       | Sex (M/F) | Coronary artery disease | Diabetes mellitus | Hyperlipidemia | Hypertension | Diabetes type 1/2 | Diabetes duration (years, mean±SD) | Vascular access for dialysis |
|---------------------------------|-----|---------------------------|-----------|-------------------------|-------------------|----------------|--------------|------------------|------------------------------------|-----------------------------|
|                                 |     | 58±13 (range 45-71)       | 6/9       | 9 (60%)                | 10 (66.7%)         | 8 (53.3%)      | 39 (61%)    | 2/8              | 17.9±5.8 (range 0.1-47)           | Temporary central venous catheter |
|                                 |     |                           |           |                         |                   |                |              |                  |                                    | Femoral vein catheter           |
|                                 |     |                           |           |                         |                   |                |              |                  |                                    | Badly function AV shunt           |
|                                 |     |                           |           |                         |                   |                |              |                  |                                    |                             |

The study patients have been receiving regular hemodialysis for periods ranging from 5 to 40 months. The median duration of use of arterio-arterial prosthetic access was 18 months.

The patients had undergone different modalities of hemodialysis accesses (6±2) (range, 1 to 9). The patients undergone dialysis through a temporary central venous catheter placed in the jugular vein (60%), femoral vein (26.6%), or through a badly function AV graft (13.3%).

Table 2: Follow up complications.

| Complication          | Total no. of patients (15) |
|-----------------------|----------------------------|
|                       | No. | %          |
| Thrombosis            | 7   | 46.7%      |
| Pseudoaneurysm        | 2   | 13.3%      |
| Infection             | 3   | 20%        |
| Mortality             | 1   | 6.7%       |
| Cumulative survival rate | 14  | 93.3%      |

AALG was reserved only for selected cases in which a conventional access not possible. All of patients had unsuitable superficial veins for the creation of a native AV fistula, or had congestive heart failure. AALG placement was indicated in fifteen patients, in five patients, one suitable vein (jugular or femoral vein) was found, where a CVC was placed, four patients had unsuitable large deep veins and Congestive heart failure was the indication in six patients.

Overall technical success was achieved in 15 (100%) cases, no complications were observed in the early postoperative course. All AALG were cannulated two weeks postoperatively.

The achieved primary and secondary patency was 73.3 % and 86.6% at 1 year and 53.3 % and 66.7 % at 3 years (Figure 3). Thrombosis of the graft during treatment with warfarin occurred in three cases in the first year on the day 20, in 47 days, and after nine months; two underwent thrombectomy successfully and one failed. Thrombosis of the graft occurs in two patients after 23 and 31 months and trial of thrombectomy failed.

The patients had undergone different modalities of hemodialysis accesses (6±2) (range, 1 to 9). The patients undergone dialysis through a temporary central venous catheter placed in the jugular vein (60%), femoral vein (26.6%), or through a badly function AV graft (13.3%).
After 27 months another patient had a whole graft infection with thrombosis and was treated by removing the graft and reconstructing the axillary artery. The cumulative survival rate for all patients was 93.3% at 3 years. No deaths were related to the AALG.

**DISCUSSION**

The arterio-arterial interposition graft is an old idea. Butt and Kountz described it for the first time in 1976. In 1979 Zingraff et al. proposed a femoro-popliteal bypass with a carotid bovine graft on a girl on hemodialysis who developed thrombosis of the superficial femoral artery. Over a period of 38 months, Zanow et al. performed this procedure on 16 patients at the femoral site (n=3) and the subclavian site (n=13) without any post-operative complications. In the present study, we established AALG for hemodialysis in those patients who had problems with conventional vascular access. The indication for AALG application was strictly controlled in our study; we defined two main indications for AALG access: exhausted upper and lower extremities accesses options including central venous occlusion and cardiac insufficiency intolerable to additional cardiac load of a high-flow AV graft.

Those patients had alternative other options as right atrial bypass grafting, axillorenal arteriovenous graft but the loop needed anastomosis to the right atrial appendage through a median sternotomy or to the renal vein, and these were thought to be complex accesses configurations. The arterio-arterial grafts on thigh were also described well previously, but thrombosis rate of the femoro-inguinal arterioarterial prosthetic loop was high.

In the present study, the demographic character of the patients showed the mean patient age was 58±13 years; 60% were women. Comorbid conditions included diabetes mellitus (66.7%), coronary heart diseases (60%), hyperlipidemia (53.3%). Additionally, most patients had a history of several vein occlusions after temporary CVC placement and multiple failed vascular accesses, thus we expect an increased risk of thrombosis after AALG procedure, postoperative oral anticoagulants routinely applied in our study.

Zanow et al. reported that the differences between AALG for vascular access in hemodialysis and conventional arterio-venous access were that a suitable vein was not needed, there wasn’t any affection on distal perfusion and the cardiac load was not increased. These differences were compatible with the observations of our study. Present study demonstrated that the AALG graft achieved primary and secondary patency rates at one year of 73.3% and 86.6% respectively and this is compatible with the secondary patency rate that was over 70% recommended by the National Kidney Foundation. Although the secondary patency rate of 66.7% at three years was lower than that reported in previously published studies, it was still acceptable with regard to the poor vascular conditions and the missing alternatives for vascular access.

The patency and intervention rate of 0.3 procedures per patient per year are comparable with results of AV grafts and meet the demands of the National Kidney Foundation Dialysis Outcomes and Quality Initiative Guidelines. Although AALG is a reliable and safe procedure for establishing vascular access for hemodialysis, it should be noted that some complications may accompany it. Five patients in our study had thrombosis of the graft, three of them occurred in first year and two later on. Thrombectomy was done for all of them with success rate 40%, but patients with failed thrombectomy passed smoothly without any ischemic manifestations. This might be due to good collateral circulation in this region and this was agreed with Butt and Kountz reports.

---

**Figure 5:** Postoperative after segmental replacement.

**Figure 6:** Postoperative contralateral loop interposition graft in patient with infected graft on the opposite side.
If the whole graft becomes infected, it is mandatory to remove the graft and reconstruct the artery. A severe infection in whole graft occurred in two patients (13.3%) after 11, 27 months. We suggest that mobilization of longer distance of the artery during the construction of AALG makes the potential reconstruction easier. Two patients had pseudoaneurysms formed after 20 and 28 months respectively at sites of repetitive needle puncture, treated successfully by excision and segmental replacement.

Zanow et al, reported that a painful reperfusion was observed in an AALG with the proximal axillary or the femoral artery as a vascular access for hemodialysis at a dialysis blood flow rate of >400mL/min, and they believed that the effect was probably caused by the higher pressure on the arterial wall. In present study, the desired sufficient extracorporeal blood flow was 300mL/min, and the painful reperfusion was not observed.

**CONCLUSION**

In selected cases and with proper indication the AALG can offer efficient alternative for vascular hemodialysis access and can improve the survival rate of such patients

Axillary-axillary loop grafting could be recommended as a "last resort" access for selected patients.

**Funding: No funding sources**

**Conflict of interest: None declared**

**Ethical approval:** The study was approved by the Institutional Ethics Committee

**REFERENCES**

1. Grassmann A, Gioberge S, Moeller S, Brown G. End-stage renal disease: Global demographics in 2005 and observed trends Artificial Organs. 2006;30:895-7.
2. Butt KM, Kountz SL. A new vascular access for hemodialysis: the arterial jump graft. Surg. 1976;79(4):476-9.
3. Rayner HC, Pisoni RL, Bommer J, Canaud B, Hecking E, Locatelli F, et al. Mortality and hospitalization in hemodialysis patients in five European countries: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant. 2004;19:108-20.
4. Port FK, Orzol SM, Held PJ, Wolfe RA. Trends in treatment and survival for hemodialysis patients in the United States. Am J Kidney Dis. 1998;32:34-8.
5. Huber TS, Carter JW, Carter RL, Seeger JM. Patency of autogenous and polytetrafluoroethylene upper extremity arteriovenous hemodialysis accesses: a systematic review. J Vasc Surg. 2003;38:1005-11.
6. Brittinger WD, Strauch M, Huber W. Shunt less hemodialysis by puncture of the subcutaneously fixed superficial femoral artery. Klin Wochenschr. 1969;47:824-6.
7. Zingraffs J, Dreake T, Di Giulio S, Lacombe M. Arterio-arterial for vascular access in hemodialysis. Now Press Med. 1979;8:283-4.
8. Zanow J, Kruger U, Petzold M, Petzold K, Miller H. Scholz H. Anterolateral prosthetic loop: a new approach for hemodialysis access J Vasc Surg. 2005;41:1007-12.
9. Kapala WA, Szcesny, Stankiewicz, W Hryncewicz W. Vascular access for chronic dialysis using the superficial femoral vein. T J Vasc. 2003;4:150-3.
10. Karp SJ, Hawsby A, Burdick JF. Axillofrenal arteriovenous graft: a new approach for dialysis access. J Vasc Surg. 2004;40:379-80.
11. Kakkos SK, Haddad R, Haddad GK, Reddy DJ, Nypaver TJ, Lin JC, et al. Results of aggressive graft surveillance and endovascular treatment on secondary patency rates of Vectra Vascular Access Grafts. J Vascular Surg. 2007;45(5):974-80.
12. Bunger CM, Kroger J, Kock L, Henning A, Klar E, Schareck W. Axillary-axillary intraarterial chest loop conduit as an alternative for chronic hemodialysis access. J Vasc Surg. 2005;42:290-5.
13. NKF-K/DOQI. Clinical Practice Guidelines for Vascular Access: update 2000 Am J Kidney Dis. 2001;37:137-81.
14. Mohamed IH, Bagul A, Doughman T, Nicholson ML. Axillary-axillary loop graft for hemodialysis access. J Vasc Access. 2011;12(3):262-3.

Cite this article as: Fareed A, Zaid N, Alkhateep YM. Axillary artery loop interposition graft (AALG) as unusual access for hemodialysis. Int Surg J 2017;4:3853-7.